Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
We aimed to evaluate the diagnostic and prognostic values of in breast cancer (BC) patients. Kaplan-Meier plotter was used to evaluate the prognostic values of and correlations between their expression and clinical characteristics were assessed based on The Cancer Genome Atlas and the Human Protein Atlas. The current study showed that P4HAs were highly expressed in BC patients with clinical stage I compared with nontumor control and elevated were correlated with poor survival outcomes. Subtypes analysis revealed that and were most expressed in HER2+ subtypes patients. Univariate analysis displayed that elevated and correlated with unfavorable recurrence-free survival in mutated patients. This study indicated the diagnostic and prognostic roles of members and broadened the biomarker fields of early diagnosis and prognostic monitoring of BC patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/bmm-2020-0323 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!